Amedisys Inc (NASDAQ:AMED) has been given a consensus recommendation of “Buy” by the twelve ratings firms that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $61.56.

AMED has been the topic of a number of recent research reports. Mizuho upgraded shares of Amedisys from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $55.00 to $65.00 in a report on Thursday, November 2nd. Benchmark Co. upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $56.00 price objective on the stock in a report on Thursday, November 2nd. Craig Hallum reiterated a “buy” rating and issued a $68.00 price objective (up from $55.00) on shares of Amedisys in a report on Thursday, November 9th. BidaskClub upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a report on Thursday, October 12th.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/amedisys-inc-amed-receives-61-56-average-price-target-from-analysts/1722681.html.

Amedisys (NASDAQ:AMED) traded up $1.40 during midday trading on Monday, hitting $56.37. 236,400 shares of the stock were exchanged, compared to its average volume of 325,230. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16. Amedisys has a 12 month low of $38.00 and a 12 month high of $65.91. The firm has a market capitalization of $1,865.50, a P/E ratio of 26.30, a PEG ratio of 1.33 and a beta of 0.68.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.02. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The company had revenue of $380.20 million for the quarter, compared to the consensus estimate of $384.59 million. During the same period last year, the company earned $0.36 earnings per share. The firm’s revenue was up 5.1% compared to the same quarter last year. sell-side analysts predict that Amedisys will post 2.23 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of AMED. UBS Asset Management Americas Inc. increased its holdings in Amedisys by 140.0% during the first quarter. UBS Asset Management Americas Inc. now owns 11,760 shares of the health services provider’s stock worth $601,000 after buying an additional 6,861 shares during the last quarter. Teachers Advisors LLC increased its holdings in Amedisys by 1.5% during the first quarter. Teachers Advisors LLC now owns 77,481 shares of the health services provider’s stock worth $3,959,000 after buying an additional 1,144 shares during the last quarter. Vanguard Group Inc. increased its holdings in Amedisys by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock worth $121,067,000 after buying an additional 63,238 shares during the last quarter. Geode Capital Management LLC increased its holdings in Amedisys by 3.2% during the first quarter. Geode Capital Management LLC now owns 231,953 shares of the health services provider’s stock worth $11,850,000 after buying an additional 7,279 shares during the last quarter. Finally, UBS Group AG increased its holdings in Amedisys by 10.4% during the first quarter. UBS Group AG now owns 11,359 shares of the health services provider’s stock worth $580,000 after buying an additional 1,067 shares during the last quarter. Institutional investors and hedge funds own 93.94% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.